Catherine M. Tangen

Fred Hutchinson Cancer Center

Public scientific profile · Unclaimed

Built from public scholarly sources. Expertise is inferred by ScienceWe from publications and has not been confirmed by the scientist.

Top expertise

Statistical Methods in Clinical Trials
Strong evidence · 2 supporting papers · latest 2025
Bladder and Urothelial Cancer Treatments
Strong evidence · 1 supporting paper · latest 2026
Coagulation, Bradykinin, Polyphosphates, and Angioedema
Solid evidence · 1 supporting paper · latest 2026
Prostate Cancer Diagnosis and Treatment
Solid evidence · 2 supporting papers · latest 2026
Genetic Associations and Epidemiology
Solid evidence · 1 supporting paper · latest 2026
Prostate Cancer Treatment and Research
Solid evidence · 2 supporting papers · latest 2026
Complement system in diseases
Solid evidence · 2 supporting papers · latest 2026
Urinary Bladder and Prostate Research
Solid evidence · 1 supporting paper · latest 2026

Estimating the Effect of Finasteride on Kallikrein Marker Levels in Blood and the Use of Converted Markers in the Four-Kallikrein Model
2026DOI PMID 41864782
Proliferation- and cytotoxic immune signatures identify chemotherapy-responsive bladder tumors in a molecular subtype dependent manner
2026DOI PMID 42399473
No Evidence of Post-Finasteride Syndrome in 267,983 Person-Years Follow-up in the Prostate Cancer Prevention Trial
2026DOI PMID 42628582
Designs Using Time-to-Event Endpoints
2025DOI
Clinical Trial in Progress: SWOG S2210, a Phase 2 Study of Neoadjuvant Carboplatin for Localized High-risk Prostate Cancer with Germline BRCA1/2 Mutations
2025DOI PMID 41354605
Polygenic risk score with KLK3 SNP-SNP interaction pairs for predicting prostate cancer aggressiveness
2026DOI PMID 42204244
Current Suggested Practices and Issues for Data and Safety Monitoring Committees in Cancer Clinical Trials
2025DOI

Affiliation evidence only — not confirmed current employment.

Source: OpenAlex · retrieved 2026-09-29